TY - JOUR
T1 - Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer
AU - Timperi, Eleonora
AU - Gueguen, Paul
AU - Molgora, Martina
AU - Magagna, Ilaria
AU - Kieffer, Yann
AU - Lopez-Lastra, Silvia
AU - Sirven, Philemon
AU - Baudrin, Laura G.
AU - Baulande, Sylvain
AU - Nicolas, André
AU - Champenois, Gabriel
AU - Meseure, Didier
AU - Vincent-Salomon, Anne
AU - Tardivon, Anne
AU - Laas, Enora
AU - Soumelis, Vassili
AU - Colonna, Marco
AU - Mechta-Grigoriou, Fatima
AU - Amigorena, Sebastian
AU - Romano, Emanuela
N1 - Funding Information:
The authors thank all the platforms and services at Curie involved in the study: 10X, Cytometry, and Pathology. High-throughput sequencing was performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09–08 (France Génomique Consortium) from the Agence Nationale de la Recherche ("Investissements d’Avenir" program), by the ITMO-Cancer Aviesan (Plan Cancer III), and by the SiRIC-Curie program (SiRIC Grant INCa-DGOS- 4654). The authors thank Maija Hollmén for the collaboration and for providing us with the antibody (STAB1); Immunologie Clinique and Olivier Lantz for their collaboration; Rodrigo Nalio Ramos, Jimena Tosello, Mercedes Tkach, Giulia Vanoni, and Arnaud Manon for technical advice; Julie Helft and Elodie Segura for the constructive discussions; Jules Gilet for bioinformatic analysis; Leclerc Renaud from the experimental pathology platform for technical support on Multiplex IHC analysis; Maud Kamal, Christophe le Tourneau, Charlotte Martinat, and all the colleagues involved in the SCANDARE and STROMA circuits; and all the patients and families. This work was supported by the following grants to E. Romano: Foundation ARC (grant no. AAP SIGN’IT 2019), Fonds Amgen France pour la Science et l’Humain; CIC IGR-Curie 1428; ANR-10-IDEX-0001-02 PSL; and ANR-11-LABX-0043; S. Amigorena: INSERM, Institut Curie, CNRS; M. Colonna: NIH (grant no. R01 CA262684). E. Timperi was supported by a postdoctoral fellowship abroad from the AIRC (2018/2020-number: 20934). M. Molgora is a recipient of the Cancer Research Institute—Lloyd J. Old Memorial Fellowship in Tumor Immunology.
Funding Information:
The authors thank all the platforms and services at Curie involved in the study: 10X, Cytometry, and Pathology. High-throughput sequencing was performed by the ICGex NGS platform of the Institut Curie supported by the grants ANR-10-EQPX-03 (Equipex) and ANR-10-INBS-09–08 (France Génomique Consortium) from the Agence Nationale de la Recherche ("Investissements d’Avenir" program), by the ITMO-Cancer Aviesan (Plan Cancer III), and by the SiRIC-Curie program (SiRIC
Funding Information:
M. Molgora reports grants from NIH and grants from Cancer Research Institute during the conduct of the study. A. Vincent-Salomon reports grants and personal fees from IBEX, Daiichi Sankyo; personal fees from Roche; grants, personal fees, and nonfinancial support from AstraZeneca; and personal fees from BMS outside the submitted work. V. Soumelis is a full-time employee at Owkin since March 2022; in addition, V. Soumelis reports grant support from Sanofi and personal fees from Leo Pharma and Aummune. M. Colonna reports grants and personal fees from NGM Biopharmaceutical during the conduct of the study; grants from Oncorus; and grants and personal fees from Vigil Neuroscience outside the submitted work; in addition, M. Colonna has a patent for TREM2 pending. S. Amigorena reports other support from INSERM, Institut Curie, CNRS during the conduct of the study; personal fees from Biomunex; grants and personal fees from Mnemo Therapeutics; and personal fees from Innate Pharma outside the submitted work. E. Romano reports grants from Fonds Amgen France pour la Science et l’Humain during the conduct of the study; Fondation BMS, Replimune, Astra Zeneca; and other support from MSD France outside the submitted work. No disclosures were reported by the other authors.
Publisher Copyright:
©2022 American Association for Cancer Research.
PY - 2022/9/15
Y1 - 2022/9/15
N2 - Tumor-associated macrophages (TAM) play a detrimental role in triple-negative breast cancer (TNBC). In-depth analysis of TAM characteristics and interactions with stromal cells, such as cancer-associated fibroblast (CAF), could provide important biological and therapeutic insights. Here we identify at the single-cell level a monocyte-derived STAB1þTREM2high lipid-associated macrophage (LAM) subpopulation with immune suppressive capacities that is expanded in patients resistant to immune checkpoint blockade (ICB). Genetic depletion of this LAM subset in mice suppressed TNBC tumor growth. Flow cytometry and bulk RNA sequencing data demonstrated that coculture with TNBC-derived CAFs led to reprogramming of blood monocytes towards immune suppressive STAB1þTREM2high LAMs, which inhibit T-cell activation and proliferation. Cell-to-cell interaction modeling and assays in vitro demonstrated the role of the inflammatory CXCL12–CXCR4 axis in CAF–myeloid cell cross-talk and recruitment of monocytes in tumor sites. Altogether, these data suggest an inflammation model whereby monocytes recruited to the tumor via the CAF-driven CXCL12–CXCR4 axis acquire protumorigenic LAM capacities to support an immunosuppressive microenvironment.
AB - Tumor-associated macrophages (TAM) play a detrimental role in triple-negative breast cancer (TNBC). In-depth analysis of TAM characteristics and interactions with stromal cells, such as cancer-associated fibroblast (CAF), could provide important biological and therapeutic insights. Here we identify at the single-cell level a monocyte-derived STAB1þTREM2high lipid-associated macrophage (LAM) subpopulation with immune suppressive capacities that is expanded in patients resistant to immune checkpoint blockade (ICB). Genetic depletion of this LAM subset in mice suppressed TNBC tumor growth. Flow cytometry and bulk RNA sequencing data demonstrated that coculture with TNBC-derived CAFs led to reprogramming of blood monocytes towards immune suppressive STAB1þTREM2high LAMs, which inhibit T-cell activation and proliferation. Cell-to-cell interaction modeling and assays in vitro demonstrated the role of the inflammatory CXCL12–CXCR4 axis in CAF–myeloid cell cross-talk and recruitment of monocytes in tumor sites. Altogether, these data suggest an inflammation model whereby monocytes recruited to the tumor via the CAF-driven CXCL12–CXCR4 axis acquire protumorigenic LAM capacities to support an immunosuppressive microenvironment.
UR - http://www.scopus.com/inward/record.url?scp=85138447860&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-22-1427
DO - 10.1158/0008-5472.CAN-22-1427
M3 - Article
C2 - 35862581
AN - SCOPUS:85138447860
SN - 0008-5472
VL - 82
SP - 3291
EP - 3306
JO - Cancer research
JF - Cancer research
IS - 18
ER -